Soaring Demand Set to Propel Gene-Circuit Cell Therapy Market to $2.95 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Gene-Circuit Cell Therapy Market Through 2025?
The market for gene-circuit cell therapy has seen significant expansion in recent times. The market, currently valued at $1.14 billion in 2024, is projected to increase to $1.38 billion in 2025, boasting a compound annual growth rate (CAGR) of 21.3%. The historical growth in this sector can be credited to the growing necessity for programmable and targeted treatments, increased funding in gene and cell therapy research and development, a rise in instances of genetic disorders and cancer, and the broadening of clinical trials for engineered cell treatments.

What's the Projected Size of the Global Gene-Circuit Cell Therapy Market by 2029?
The market size of gene-circuit cell therapy is predicted to witness a significant escalation in the ensuing years, positioning itself at $2.95 billion in 2029 with a compound annual growth rate (CAGR) of 20.9%. Several triggers for this anticipated growth in the estimated period include a rising tendency towards in-vivo delivery and non-viral platforms, enhanced regulatory backing and streamlined sanction pathways, burgeoning financial support from pharmaceutical firms and venture capital, augmented demand for ready-to-use allogeneic cell therapies, along with increased manufacturing capacity and gene synthesis services. Pivotal trends that will shape the market in the forecast period encompass progress in synthetic gene circuit design, revolutionary safety switches and programmable control systems, improvements in scalable and automated manufacturing, and advanced integration with real-time monitoring and bioinformatics.

View the full report here:
https://www.thebusinessresearchcompany.com/report/gene-circuit-cell-therapy-global-market-report

Top Growth Drivers in the Gene-Circuit Cell Therapy Industry: What's Accelerating the Market?
The increase in genetic disorders is predicted to energize the expansion of the gene-circuit cell therapy market. Genetic disorders result from variations or abnormalities in DNA and can be passed down through generations or develop randomly, impacting health, growth, or bodily functions. The escalating occurrence of genetic disorders can be attributed to enhanced awareness and advancements in diagnostic technologies, which facilitate early and accurate identification of previously undiagnosed conditions. Gene-circuit cell therapy improves the management of genetic disorders by providing highly specialized and adaptable therapies, thereby making them perfect for diseases with complicated or erstwhile untreatable genetic defects. This therapy betters patient outcomes by meticulously modifying or regulating cellular functions, mitigating disease symptoms, and offering potential functional remedies. The Cystic Fibrosis Trust reported that the number of patients diagnosed with cystic fibrosis rose from 10,908 in 2021 to 11,148 in 2022. Consequently, the escalating instance of genetic disorders is catalyzing the growth of the gene-circuit cell therapy market. Enhancements in genomics and tailored treatment methodologies have led to a rise in personalized medicine, thereby fueling the gene-circuit cell therapy market's growth. Personalized medicine is a medical model that customizes treatment and preventive strategies based on an individual's unique genetic makeup, lifestyle, and environment. The rising acceptance of personalized medicine can be credited to advances in genomics, which facilitate the pinpoint identification of genetic variations and the customization of treatments to individuals. Gene-circuit cell therapy supplements personalized medicine by providing precise and programmable treatment strategies, thus making it a perfect fit for complex and chronic diseases. It enhances therapy precision by modulating interventions to cater to individual patient needs, thereby augmenting the efficacy of treatment and overall health outcomes. According to the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 26 new personalized medicines in 2023, a considerable rise from the 12 approved in 2022. Therefore, the increasing adoption of personalized medicine is stimulating the gene-circuit cell therapy market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28233&type=smp

What Trends Will Shape the Gene-Circuit Cell Therapy Market Through 2029 and Beyond?
Leading entities in the gene-circuit cell therapy market are concentrating their efforts on creating sophisticated therapeutic platforms. These include CRISPR-based gene-editing systems which are designed to improve the accuracy of treatment, enhance therapeutic results, and tackle genetic diseases once regarded as untreatable. CRISPR-based gene editing systems refer to revolutionary techniques that allow for exact alterations to the genome. This enables the rectification of genetic defects or the insertion of therapeutic genes directly into cells. For example, in December 2023, United States biopharmaceutical firm Vertex Pharmaceuticals Inc. collaborated with U.S. biotech research firm, CRISPR Therapeutics Inc. They obtained a conditional marketing authorization from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This product is recommended for patients aged 12 and above sufferers of sickle cell disease (SCD) and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). CASGEVY operates by modifying the patient's hematopoietic stem cells to jump-start fetal hemoglobin production, which lessens or removes disease symptoms and potentially offers a practical cure for these conditions.

What Are the Main Segments in the Gene-Circuit Cell Therapy Market?
The gene-circuit cell therapy market covered in this report is segmented as

1) By Product Type: Autologous, Allogeneic
2) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Transcription Activator-Like Effector Nuclease (TALEN), Zinc Finger Nuclease (ZFN), Other Technologies
3) By Application: Oncology, Genetic Disorders, Infectious Diseases, Other Applications
4) By End-User: Hospitals And Clinics, Research Institutes, Biotechnology And Pharmaceutical Companies, Other End Users

Subsegments:
1) By Autologous: Chimeric Antigen Receptor (CAR)-T Cell Therapies, T-Cell Receptor (TCR)-T Cell Therapies, Natural Killer (NK) Cell Therapies, Stem Cell-Based Therapies
2) By Allogeneic: Off-The-Shelf Chimeric Antigen Receptor (CAR)-T Cell Therapies, Off-The-Shelf Natural Killer (NK) Cell Therapies, TT-Cell Receptor (TCR)-T Cell Therapies, Stem Cell-Derived Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28233&type=smp

Which Top Companies are Driving Growth in the Gene-Circuit Cell Therapy Market?
Major companies operating in the gene-circuit cell therapy market are Tmunity Therapeutics Inc., Ginkgo Bioworks Holdings Inc., Arcellx Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Intellia Therapeutics Inc., Orchard Therapeutics plc, Fate Therapeutics Inc., Rubius Therapeutics Inc., BlueRock Therapeutics LP (a subsidiary of Bayer AG), Precigen Inc., SparingVision, Alaunos Therapeutics Inc., Cartesian Therapeutics Inc., Lyell Immunopharma Inc., Synlogic Inc., Senti Biosciences Inc., Autolus Therapeutics plc, Cellectis S.A., and Sotio Biotech.

Which Regions Will Dominate the Gene-Circuit Cell Therapy Market Through 2029?
North America was the largest region in the gene-circuit cell therapy market in 2024. The regions covered in gene-circuit cell therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28233

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.